WO2007077313A1 - Nouveaux derives d’oximes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent - Google Patents
Nouveaux derives d’oximes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent Download PDFInfo
- Publication number
- WO2007077313A1 WO2007077313A1 PCT/FR2006/002778 FR2006002778W WO2007077313A1 WO 2007077313 A1 WO2007077313 A1 WO 2007077313A1 FR 2006002778 W FR2006002778 W FR 2006002778W WO 2007077313 A1 WO2007077313 A1 WO 2007077313A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- phenyl
- methyl
- ethoxy
- pyrrolo
- pyridin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present invention relates to novel heterocyclic oximes derivatives, process for their preparation and pharmaceutical compositions containing them.
- the compounds described in the present invention are new and have particularly advantageous pharmacological properties: they are excellent hypoglycemic and lipid-lowering agents.
- non-insulin-dependent type II diabetes remains unsatisfactory despite the placing on the market of numerous oral hypoglycemic agents intended to facilitate the secretion of insulin and to promote its action at the peripheral target tissues.
- hypoglycemic agents have significant side effects (hepatic, cardiac, hematopoietic) that limit their long-term use in the treatment of non-insulin-dependent diabetes type II
- hyperlipidemia is often observed in diabetics (Diabetes Care, 1995, 18 (supplement 1), 86/8/93).
- diabetes Care, 1995, 18 (supplement 1) 86/8/93.
- hyperglycemia promotes the risk of cardiovascular disease in diabetics.
- Hyperglycemia, hyperlipidemia and obesity have become pathologies of the modern world marked by a large amount of food intake and a chronic lack of exercise.
- the compounds of the present invention in addition to their novelty, meet these pharmacological criteria and are excellent hypoglycemic and lipid-lowering agents.
- the present invention relates more particularly to the compounds of formula (I)
- R 1 represents an aryl, heteroaryl or cycloalkyl (C 3 -C 8 ) group
- R 2 represents a hydrogen atom, or an alkyl group (C 1 -C 6) linear or branched, aryl, or aryl- (C 1 -C 6) linear or branched,
- X represents a hydrogen or halogen atom, or a linear or branched (C 1 -C 6 ) alkyl group
- R 3 and R 4 identical or different, represent a hydrogen or halogen atom, or an alkyl group (C 1 -C 6) linear or branched alkoxy (C 1 -C 6) linear or branched alkylamino (Ci-C 6 ) linear or branched, or dialkylamino (C 1 -C 6 ) linear or branched, -
- A represents a (C 1 -C 6 ) alkylene chain of which a CH 2 group may be replaced by a heteroatom selected from oxygen or sulfur, or by a group NR a (where Ra represents a hydrogen atom or an alkyl group ( C 1 -C 6 ) linear or branched),
- B represents a linear or branched (C 1 -C 6 ) alkyl or linear or branched (C 2 -C 6 ) alkenyl group, these groups being substituted by a group of formula (H):
- R 5 represents a group -COOR and R 6 represents a group -OR 'where R and R', which are identical or different, each represent a hydrogen atom, or a linear or branched (C 1 -C 6 ) alkyl group unsubstituted or substituted by one or more halogen atoms,
- aryl means a phenyl, naphthyl or biphenyl group, these groups being able to be partially hydrogenated
- heteroaryl means any mono or bicyclic aromatic group containing 5 to 10 members, which may be partially hydrogenated on one ring in the case of bicyclic heteroaryls, and containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulfur,
- the aryl and heteroaryl groups so defined may be substituted by 1 to 3 groups selected from alkyl (C 1 -C 6) linear or branched polyhaloalkyl (C 1 -C 6) linear or branched alkoxy (C 1 -C 6) linear or branched hydroxy, carboxy, formyl, NR b R c (wherein R b and R 0 , identical or different, represent a hydrogen atom, a linear or branched (C 1 -C 6 ) alkyl, aryl or heteroaryl ), ester, amido, nitro, cyano, or halogen atoms,
- pharmaceutically acceptable acids mention may be made, without limitation, of hydrochloric, hydrobromic, sulfuric, phosphonic, acetic, trifluoroacetic, lactic, pyruvic, malonic, succinic, glutaric, fumaric, tartaric, maleic, citric, ascorbic, methanesulphonic and camphoric acids. , oxalic, etc.
- pharmaceutically acceptable bases include, but are not limited to, sodium hydroxide, potassium hydroxide, triethylamine, tertbutylamine and the like.
- the preferred compounds of the invention are the compounds of formula (I) for which R 1 represents an aryl group and more particularly phenyl.
- the preferred R 2 group of the compounds of formula (I) according to the invention is the alkyl group and more particularly methyl.
- the compounds of formula (I) according to the invention are derivatives for which D with the ring to which it is fused represent an 1H-pyrrolo [2,3-b] pyridine system.
- the preferred group for R 3 and R 4 is hydrogen.
- A represents an alkylene chain in which a CH 2 group is replaced by an oxygen atom.
- the invention relates to the compounds of formula (I) for which A represents an ethyleneoxy group.
- X preferably represents a hydrogen atom.
- the preferred R 5 group is the COOH or COOMe group.
- the preferred group R 6 is the group OEt or OCH 2 CF 3 .
- the preferred group B is the group -CH 2 -CH (R 5 ) (R 6 ) and more particularly the group -CH 2 -CH (R 5 ) (R 6 ) in which R 5 represents a group COOH, COOMe or COOEt and R 6 represents a methoxy, ethoxy or trifluoroethoxy group.
- the invention relates to the compounds of formula (I) having a 1H-pyrrolo [2,3-e] pyridine structure in which: X represents a hydrogen atom,
- R 1 represents a phenyl, cyclopropyl, cyclopentyl or cyclohexyl group
- A represents a chain -CH 2 -CH 2 -O-
- R 2 represents a methyl group
- R 3 and R represent simultaneously a hydrogen atom
- B represents a group -CH 2 -CH (R 5 ) (R 6 ) in which R 5 represents a grouping
- R 6 represents an ethoxy or trifluoroethoxy group.
- the present invention also relates to the process for preparing the compounds of formula (I), characterized in that a compound of formula (III) is used as starting material:
- An advantageous variant relates to the process for preparing the compounds of formula (I), characterized in that a compound of formula (III) is used as starting material:
- Another aspect of the invention also relates to the compounds of formula (V):
- D, X, A, R 1 , R 3 , R 4 and B are as defined in the compounds of formula (I), useful as synthetic intermediates for the compounds of formula (I) and as hypoglycemic and hypolipidemic agents.
- the preferred compounds of formula (V) according to the invention are those for which R 1 represents a (C 3 -C 8 ) cycloalkyl group.
- the compounds of the present invention possess very valuable pharmacological properties.
- They can be used as inhibitors of Paldose reductase, to improve cognitive functions in dementia and complications of diabetes, diseases intestinal inflammatory, myotonic dystrophies, pancreatitis, arteriosclerosis, xanthoma.
- the activity of these compounds is also recommended for the treatment and / or prophylaxis of other diseases including type I diabetes, hypertriglyceridemia, syndrome X, insulin resistance, dyslipidemia in diabetics, hyperlipidemia , hypercholesterolemia, high blood pressure, heart failure, cardiovascular diseases including atherosclerosis.
- diseases including type I diabetes, hypertriglyceridemia, syndrome X, insulin resistance, dyslipidemia in diabetics, hyperlipidemia , hypercholesterolemia, high blood pressure, heart failure, cardiovascular diseases including atherosclerosis.
- these compounds are indicated for use in the regulation of appetite, particularly in the regulation of food intake in subjects suffering from disorders such as obesity, anorexia, bulimia and anorexia nervosa. .
- these compounds can be used in prevention or for the treatment of hypercholesterolemia, obesity with beneficial effects on hyperlipidemia, hyperglycemia, osteoporosis, glucose intolerance, resistance to insulin or diseases in which Pinsulin resistance is a secondary pathophysiological mechanism.
- these compounds reduces total cholesterol, body weight, leptin resistance, plasma glucose, triglycerides, LDL, VLDL and plasma free fatty acids. They can be used in combination with HMG CoA reductase inhibitors, fibrates, nicotinic acid, cholestyramine, colestipol, probucol, GLP1, metformin, biguanides or glucose reabsorption inhibitors, and may be administered together or at different times to act synergistically in the treated patient.
- compositions according to the invention mention may be made more particularly of those which are suitable for oral, parenteral, nasal, percutaneous, rectal, perlingual, ocular or respiratory administration and in particular simple or coated tablets, sublingual tablets, sachets, packets, capsules, glossettes, tablets, suppositories, creams, ointments, dermal gels and oral or injectable ampoules.
- the dosage varies according to the sex, age and weight of the patient, the route of administration, the nature of the therapeutic indication, or possibly associated treatments and ranges between 0.1 mg and 1 g per 24 hours. in 1 or more takes.
- the present invention also relates to a new combination between a heterocyclic derivative of formula (I) or (V) as defined above and an antioxidant agent for obtaining pharmaceutical compositions useful in the treatment and / or prevention of obesity and overweight characterized by a body weight index greater than 25.
- the antioxidants according to the invention are more particularly anti-free radical scavengers or free radical scavengers, antilipoperoxidizing agents, chelating agents or agents capable of regenerating endogenous antioxidants such as glutathione, vitamin C or vitamin E, as well as their addition salts with a pharmaceutically acceptable acid or base.
- the antioxidant agent of the combination according to the invention is more preferably represented by quinone derivatives such as ubiquinone or coenzyme Q 10 , which acts as a scavenger of free radicals but which is also capable of regenerating vitamin E .
- the preferred combination according to the invention is (2S) -3- [4- (2- ⁇ 6 - [(methoxyimino) (phenyl) methyl] -1H-pyrrolo [2,3-b] pyridine 1-yl ⁇ ethoxy) phenyl] -2- (2,2,2-trifluoroethoxy) propanoic acid and coenzyme Q 10 .
- the combination according to the invention has quite surprising pharmacological properties: the Applicant has in fact demonstrated the existence of a synergy between the two compounds of the combination which makes it possible to obtain a very significant reduction.
- body fat making it useful in the treatment and / or prevention of obesity and overweight characterized by a body weight index greater than 25.
- Obesity in the United States reaches 20% of men and 25% of women.
- Obesity can have several origins: they can occur as a result of deregulation of food intake, hormonal dysregulation or following administration of treatment: Type II anti-diabetic therapy with sulfonylureas results in weight gain in patients. Also in type I diabetes (insulin-dependent), insulin therapy is also a source of body weight gain in patients (In Progress in Obesity Research, 8 th International Congress on Obesity, 1999, 739-746; Armais of Internai Medicine, 1998, 128, 165-175).
- Obesity and overweight are well-established risk factors for cardiovascular disease: they are associated with an increased significance of the risk of stroke, non-msulino-dependent diabetes because they predispose to insulin resistance , dyslipidemia and the appearance of macro-vascular diseases (nephropathies, retinopathies, angiopathies).
- the combination according to the invention achieves a weight loss that even moderate significantly reduces all the risk factors associated with obesity (Int, J. Obes., 1997, 21, 55-9, MJ Obes., 1992, 21, S5-9).
- the combination according to the invention thus finds its utility in the treatment and / or prevention of obesity and weight overload characterized by a body index greater than 25.
- the invention therefore relates to the use of the association between a compound of formula (I) or (V) and an antioxidant agent for obtaining pharmaceutical compositions intended for the treatment and / or prevention of obesity and overweight characterized by a body index greater than 25 and less than 30 .
- the combination according to the invention is useful in the treatment and / or prevention of obesity and overweight characterized by a body index greater than 25 and less than 30 induced by a therapeutic treatment, such as the treatment of type I or IL diabetes
- a therapeutic treatment such as the treatment of type I or IL diabetes
- the invention therefore relates to the use of the combination between a compound of formula (I) or (V) and an antioxidant agent for obtaining pharmaceutical compositions intended for treatment and / or prevention obesity and overweight characterized by a body index greater than 25 and less than 30 induced by a therapeutic treatment, such as treatment of type I or IL diabetes
- the invention also relates to pharmaceutical compositions containing the combination of a compound of formula (I) or (V) and an antioxidant as defined above in combination with one or more pharmaceutically acceptable excipients.
- compositions according to the invention mention may be made more particularly of those which are suitable for oral, parenteral, nasal administration, single or sugar-coated tablets, sublingual tablets, capsules, lozenges, suppositories, creams, ointments , dermal gels, etc.
- the invention relates to pharmaceutical compositions containing a compound of formula (I) or (V) as defined above and an antioxidant such as coenzyme Q 10 or vitamin E in combination with one or more pharmaceutically acceptable excipients.
- the dosage varies according to the sex, age and weight of the patient, the route of administration, the nature of the therapeutic indication or any associated treatments and ranges between 0.1 mg and 1 g of each component of the association by 24 hours in one or more catches.
- Step A Cyclopropyl (1H-pyrrolo [2,3-b] pyridin-6-yl) methanone
- Stage B 3- (4 ⁇ ⁇ 2- ⁇ - (Cychpropylcarbonyl) -1H-pyiro [2,3-b] pyridin-1-yl] -thio [phenyl] -2-methoxypropanoate methyl
- the crude is purified by chromatography on silica gel (petroleum ether / ethyl acetate: 9/1, 8/2 then 7/3) to yield the title product in the form of a yellowish solid.
- Step B 3- ⁇ 4- ⁇ 2- [6 ⁇ (cyclohexylcarbonyl) LII ⁇ ⁇ f pyn olo [2, 3-bJpyridin-yl] ethoxy ⁇ phenyl) -2-ethoxypropanoate of proceduretkyle
- Preparation 3 are dissolved in 30 mL of a 50/50 water / tetrahydrofuran mixture. Then, 53 mg (1.26 mmol) of lithium hydroxide are added. The reaction is stirred 1 hour to ambient temperature. Tetrahydrofuran is then evaporated under reduced pressure. The residue is acidified to pH 3 with aqueous acetic acid and extracted 3 times with 20 mL of ethyl acetate. The organic phases are dried over magnesium sulphate, filtered and evaporated under reduced pressure. The residue is purified by chromatography on silica gel (pure dichloromethane and then dichloromethane / methanol: 95/5 then 90/10) to yield the title product in the form of a yellow oil.
- the pH is then brought to 1 with 10% hydrochloric acid and the resulting solution is stirred for 2 hours at room temperature. ambient temperature.
- the pH of the solution is brought to 9 with a concentrated solution of ammonia and the aqueous phase extracted twice with 20 ml of dichloromethane.
- the organic phases are dried over magnesium sulphate, filtered and evaporated under reduced pressure. After purification by chromatography on silica gel (pure dichloromethane and then dichloromethane / methanol: 99/1), the title compound is obtained in the form of a yellow solid.
- Step C 2-Ethoxy-S- [4- (2 ⁇ ⁇ 6 - [(E) - (methoxyimino) (phenyl) methyl] -1H-pyr ⁇ -olo [2 t- b] pyridin-1-yl Methyl ethoxy) phenyl] propanoate
- the aqueous phase is extracted twice with 30 ml of dichloromethane.
- the organic phases are dried over magnesium sulphate, filtered and evaporated under reduced pressure.
- the crude product obtained is purified by chromatography on silica gel (petroleum ether / ethyl acetate: 8/2) and gives the title product in the form of a yellow oil.
- Example 2 The compound obtained in Example 1 (0.360 g) is dissolved in 20 ml of a 50/50 water / tetrahydrofuran mixture. Then, 0.094 g of lithium hydroxide is added. The reaction is stirred for 2 hours at room temperature. The tetrahydrofuran is then evaporated and the residue obtained is acidified to pH 3 with aqueous acetic acid. This aqueous phase is extracted 3 times with 50 ml of dichloromethane. The combined organic phases are dried over magnesium sulphate, filtered and evaporated under reduced pressure. The crude is purified by chromatography on silica gel (dichloromethane / methanol: 97/3) and leads to the title product in the form of a slightly yellow gum.
- Example 2 The compound obtained in Example 2 (0.140 g) is dissolved in 3 ml of tetrahydrofuran and cooled to 0 ° C. Then 0.035 g (0.84 mmol) of lithium hydroxide monohydrate dissolved in 5 ml of water are added. . The reaction is stirred for 3 hours at 0 ° C. at room temperature. The solvent is evaporated. The residue obtained is washed with 10 mL of diethyl ether. The aqueous phase is acidified to pH 3 with aqueous acetic acid. It is then extracted 3 times with 10 mL of ether. The organic phases are dried over magnesium sulphate, filtered and evaporated under reduced pressure. The residue is purified by chromatography on silica gel (dichloromethane / methanol 95/5).
- Example 5 The title acid is obtained from the compound obtained in Example 5 (0.900 g) according to the procedure used for Example 6, in the form of a yellow foam.
- EXAMPLE 12 344-2- ⁇ 5 - [fMéth ⁇ CTimmQ ⁇ phénynméthyn-lH-pvrrolor23 b1pvridm--l-yl. ⁇ Ethoxy) phenyl] -2- (2 "2,2-trîflworoétlioxy) methyl propaHoate
- Example 11 The compound obtained in Example 11 (0.500 g) is dissolved in 10 mL of tetrahydrofuran and cooled to 0 ° C. Then 0.113 g (2.70 mmol) of lithium hydroxide monohydrate dissolved in 17 mL of water are added. The reaction is stirred for 2 hours at 0 ° C and the solvent is evaporated. The residue is taken up in 10 ml of water and acidified to pH 3 with aqueous acetic acid. It is extracted 3 times with 10 mL of dichloromethane. The organic phases are dried over magnesium sulfate, filtered and evaporated.
- EXAMPLE 14 S-O-C 1-6 -alkyl-8-hydroxy-1-ylmethyl-1H-pyrrolo [p -benzyl-1-yl] ethoxy] phenyl-2- (2,2,2-trifluoroethoxy) propanoic acid
- Example 12 The compound obtained in Example 12 (0.500 g) is dissolved in 10 mL of tetrahydrofuran and cooled to 0 ° C. Then 0.113 g (2.70 mmol) of lithium hydroxide monohydrate dissolved in 17 mL of water are added. The reaction is stirred for 2 hours at 0 ° C and the solvent is evaporated. The residue is taken up in 10 ml of water and acidified to pH 3 with aqueous acetic acid. It is extracted 3 times with 10 mL of dichloromethane. The organic phases are dried over magnesium sulfate, filtered and evaporated.
- Step A 4-C-chloro-1- (triisopropylhilyl) -1H-pyrrolo [2, S-b] pyridine
- reaction is stirred for 3 hours under reflux. It is hydrolysed with 50 ml of a saturated solution of ammonium chloride and extracted 3 times with 50 ml of dichloromethane. The organic phases are dried over magnesium sulphate, filtered and evaporated under reduced pressure.
- Step B [4-Chloro-1- (triisopropylsilyl) -1H-pyrrolo [2,3-h] pyrimid-5-yl] phenyfymethanil
- Step B The compound obtained in Step B (1.4 g) is dissolved in 90 ml of toluene and 2.93 g (33.70 mmol) of manganese dioxide are added. Dean Stark's camera is positioned. The reaction is stirred for 18 hours under reflux and then allowed to return to ambient temperature. The mixture is then filtered on celite and the filtrate is evaporated.
- Example 15 The compound obtained in Example 15 (0.300 g) is dissolved in tetrahydrofuran and cooled to 0 ° C. Then 0.064 g (1.53 mmol) of lithium hydroxide monohydrate dissolved in 10 mL of water are added. The reaction is stirred 1 hour and a half from 0 ° C to room temperature. The solvent is evaporated and the residue is dissolved in 10 mL of water. After acidification with aqueous acetic acid, it is extracted 3 times with 10 ml of dichloromethane. The organic phases are dried over magnesium sulfate, filtered and evaporated. The white powder obtained is washed with hexane, filtered on sintered glass and dried under vacuum. Melting point: 186 ° C.
- Acute toxicity was assessed after oral administration to batches of 8 mice (26 ⁇ 2 g). The animals were observed at regular intervals during the first day and daily for two weeks following treatment. The LD 50 , resulting in the death of 50% of the animals, was evaluated and showed the low toxicity of the compounds of the invention.
- the 10-week old ob / ob male mouse (Harlan) is used for in vivo testing. These animals are kept under a 12-hour light-dark cycle at 25 ° C. This mouse has a basal hyperglycemia of 2 g / l. Animals are randomized to their blood glucose levels to form groups of eight. The orally tested compounds are dissolved in a mixture of hydroxyethyl cellulose (1% HEC) to be administered at 3 mg / kg in a volume of 10 ml / kg, once a day for four days. The control group receives the solvents under the same conditions as the treated groups. Product activity is assessed by measuring blood glucose, triglyceride and insulin levels 24 hours after the last administration and by daily measurement of body weight.
- HEC hydroxyethyl cellulose
- the compounds of the invention show a very good ability to reduce blood glucose comparable to the effects obtained with Rosiglitazone, the reference substance.
- the compound of Example 32 administered at a dose of 3 mg / kg, shows a 37% reduction in triglyceride level compared with the control group, a reduction of insulinemia of 23% compared to control group and a 43% reduction in blood glucose compared to control.
- mice 8 to 12 weeks old Male C57 Black 6 ob / ob mice 8 to 12 weeks old were used. After quarantine for one week, they were weighed and randomized according to their weight, and 6 homogeneous groups (not significantly different starting weight) were formed. After being weighed, the different combinations to be tested are injected intraperitoneally once a day for 7 days. The molecules are injected into a 5% DMSO / 15% Solutol / H 2 O H 2 O solution heated to 65 ° C. to ensure good dissolution. The solution is further preheated before injection. The mice are weighed daily and the weight obtained after 7 days of treatment is recorded. The results obtained clearly show:
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Gynecology & Obstetrics (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Pregnancy & Childbirth (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06847063A EP1966204A1 (fr) | 2005-12-20 | 2006-12-19 | Nouveaux derives d oximes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
AU2006334310A AU2006334310A1 (en) | 2005-12-20 | 2006-12-19 | Novel heterocyclic oxime derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
BRPI0620190-3A BRPI0620190A2 (pt) | 2005-12-20 | 2006-12-19 | derivados de oximas heterocìclicas, respectivo processo de preparação e composições farmacêuticas que os contêm |
JP2008546513A JP2009520007A (ja) | 2005-12-20 | 2006-12-19 | 新規な複素環オキシム誘導体、その製造方法及びこれらを含む薬剤組成物 |
EA200801566A EA014317B1 (ru) | 2005-12-20 | 2006-12-19 | Новые гетероциклические соединения оксима, способ их получения и фармацевтические композиции, которые их содержат |
CA002634320A CA2634320A1 (fr) | 2005-12-20 | 2006-12-19 | Nouveaux derives d'oximes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US12/086,785 US20090274674A1 (en) | 2005-12-20 | 2006-12-19 | Heterocyclic Oxime Compounds, Process for Their Preparation and Pharmaceutical Compositions Containing Them |
NO20082821A NO20082821L (no) | 2005-12-20 | 2008-06-25 | Nye heterocykliske oksim-derivater, fremgangsmaten for fremstilling derav samt farmasoytiske sammensetninger inneholdende slike |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0512924 | 2005-12-20 | ||
FR0512924A FR2894965B1 (fr) | 2005-12-20 | 2005-12-20 | Nouveaux derives d'oximes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007077313A1 true WO2007077313A1 (fr) | 2007-07-12 |
Family
ID=37055975
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2006/002778 WO2007077313A1 (fr) | 2005-12-20 | 2006-12-19 | Nouveaux derives d’oximes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
Country Status (15)
Country | Link |
---|---|
US (1) | US20090274674A1 (fr) |
EP (1) | EP1966204A1 (fr) |
JP (1) | JP2009520007A (fr) |
KR (1) | KR20080077030A (fr) |
CN (1) | CN101374837A (fr) |
AR (1) | AR058573A1 (fr) |
AU (1) | AU2006334310A1 (fr) |
BR (1) | BRPI0620190A2 (fr) |
CA (1) | CA2634320A1 (fr) |
EA (1) | EA014317B1 (fr) |
FR (1) | FR2894965B1 (fr) |
MA (1) | MA30068B1 (fr) |
NO (1) | NO20082821L (fr) |
WO (1) | WO2007077313A1 (fr) |
ZA (1) | ZA200805976B (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010026771A1 (fr) * | 2008-09-08 | 2010-03-11 | 日本曹達株式会社 | Composé hétérocyclique azoté et son sel, et agent bactéricide pour des applications en agriculture ou horticulture |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001057002A1 (fr) * | 2000-02-02 | 2001-08-09 | Les Laboratoires Servier | Derives d'azoles condenses et leur utilisation comme agents hypoglycemiants |
EP1502590A1 (fr) * | 2003-07-28 | 2005-02-02 | Les Laboratoires Servier | Dérivés d'oximes hétérocycliques, leur procédé de préparation et leur utilisation dans le traitement du diabète de type II |
WO2005099694A1 (fr) * | 2004-03-31 | 2005-10-27 | Les Laboratoires Servier | Association entre un compose heterocyclique et un agent antioxydant et son utilisation pour le traitement de l’obesite |
-
2005
- 2005-12-20 FR FR0512924A patent/FR2894965B1/fr not_active Expired - Fee Related
-
2006
- 2006-12-19 US US12/086,785 patent/US20090274674A1/en not_active Abandoned
- 2006-12-19 JP JP2008546513A patent/JP2009520007A/ja active Pending
- 2006-12-19 CN CNA200680052931XA patent/CN101374837A/zh active Pending
- 2006-12-19 CA CA002634320A patent/CA2634320A1/fr not_active Abandoned
- 2006-12-19 EA EA200801566A patent/EA014317B1/ru not_active IP Right Cessation
- 2006-12-19 EP EP06847063A patent/EP1966204A1/fr not_active Withdrawn
- 2006-12-19 WO PCT/FR2006/002778 patent/WO2007077313A1/fr active Application Filing
- 2006-12-19 ZA ZA200805976A patent/ZA200805976B/xx unknown
- 2006-12-19 KR KR1020087017808A patent/KR20080077030A/ko not_active Application Discontinuation
- 2006-12-19 AU AU2006334310A patent/AU2006334310A1/en not_active Abandoned
- 2006-12-19 BR BRPI0620190-3A patent/BRPI0620190A2/pt not_active IP Right Cessation
- 2006-12-20 AR ARP060105638A patent/AR058573A1/es unknown
-
2008
- 2008-06-19 MA MA31052A patent/MA30068B1/fr unknown
- 2008-06-25 NO NO20082821A patent/NO20082821L/no not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001057002A1 (fr) * | 2000-02-02 | 2001-08-09 | Les Laboratoires Servier | Derives d'azoles condenses et leur utilisation comme agents hypoglycemiants |
EP1502590A1 (fr) * | 2003-07-28 | 2005-02-02 | Les Laboratoires Servier | Dérivés d'oximes hétérocycliques, leur procédé de préparation et leur utilisation dans le traitement du diabète de type II |
WO2005099694A1 (fr) * | 2004-03-31 | 2005-10-27 | Les Laboratoires Servier | Association entre un compose heterocyclique et un agent antioxydant et son utilisation pour le traitement de l’obesite |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010026771A1 (fr) * | 2008-09-08 | 2010-03-11 | 日本曹達株式会社 | Composé hétérocyclique azoté et son sel, et agent bactéricide pour des applications en agriculture ou horticulture |
JP5281647B2 (ja) * | 2008-09-08 | 2013-09-04 | 日本曹達株式会社 | 含窒素ヘテロ環化合物およびその塩並びに農園芸用殺菌剤 |
Also Published As
Publication number | Publication date |
---|---|
EP1966204A1 (fr) | 2008-09-10 |
CA2634320A1 (fr) | 2007-07-12 |
MA30068B1 (fr) | 2008-12-01 |
CN101374837A (zh) | 2009-02-25 |
FR2894965A1 (fr) | 2007-06-22 |
US20090274674A1 (en) | 2009-11-05 |
AU2006334310A1 (en) | 2007-07-12 |
NO20082821L (no) | 2008-08-26 |
EA200801566A1 (ru) | 2008-12-30 |
EA014317B1 (ru) | 2010-10-29 |
AR058573A1 (es) | 2008-02-13 |
BRPI0620190A2 (pt) | 2011-11-01 |
ZA200805976B (en) | 2009-11-25 |
KR20080077030A (ko) | 2008-08-20 |
FR2894965B1 (fr) | 2008-01-25 |
JP2009520007A (ja) | 2009-05-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113194958B (zh) | THRβ受体激动剂化合物及其制备方法和用途 | |
CA2620662C (fr) | Derives de pyrrolopyridine et leurs utilisations comme modulateurs des recepteurs ppar | |
WO2008081096A2 (fr) | Derives quinolinyliques, leur procede de preparation. les compositions pharmaceutiques qui les contiennent et leur utilisation comme agents hypoglycemiants et hypoli pemiants | |
EP2158201B1 (fr) | Derives de 7-alkynyl-1,8-naphthyridones, leur preparation et leur application en therapeutique | |
WO2008006969A2 (fr) | Nouveaux derives tetracycuques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
EP2158194B1 (fr) | Dérivés de 7 -alkynyl-1,8-naphthyridones, leur préparation et leur application en thérapeutique | |
EP1252150B1 (fr) | Derives d'azoles condenses et leur utilisation comme agents hypoglycemiants | |
EP1844029B1 (fr) | Nouveaux derives d'oximes heterocycliques, leur procede de preparation et leur utilisation comme agents hypoglycemiants et hypolipemiants | |
WO2007077313A1 (fr) | Nouveaux derives d’oximes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
KR100753860B1 (ko) | 유기 셀레늄 함유 화합물 및 이들 화합물의 용도 | |
FR2881137A1 (fr) | Nouveaux derives d'oximes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
WO2003027108A1 (fr) | Derives heterocycliques et leur utilisation en tant qu'agents hypoglycemiants et hypolipemiants | |
FR2898125A1 (fr) | Nouveaux derives heterocycliques cycloalkyles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
FR2845998A1 (fr) | Nouveaux composes benzoxazoles ou oxazolopyridines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
CN117327057A (zh) | 一类作为甲状腺激素受体激动剂的三嗪二酮类化合物及其合成、用途 | |
EP2838899B1 (fr) | Dérivés de thiazolidinedione, leur préparation et leur utilisation dans le traitement des cancers | |
FR2921366A1 (fr) | Nouveaux derives heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006847063 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008061037 Country of ref document: EG Ref document number: 2006334310 Country of ref document: AU Ref document number: 569224 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2634320 Country of ref document: CA Ref document number: 12086785 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2008/008059 Country of ref document: MX Ref document number: 2008546513 Country of ref document: JP Ref document number: 5389/DELNP/2008 Country of ref document: IN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2006334310 Country of ref document: AU Date of ref document: 20061219 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2006334310 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10823 Country of ref document: GE Ref document number: 200801566 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087017808 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200680052931.X Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2006847063 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0620190 Country of ref document: BR Kind code of ref document: A2 Effective date: 20080620 |